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moting local thrombogenesis (mortality at 14 days 22% versus 10%, p = 0.026). interest- 
ingly, this difference in mortality was almost entirely observed within the subgroup of 
patients treated with heparin alone instead of lhrombolysis or embolectomy as adjuncts 
to heparin (25% versus 7.2%, p=0.007), despite similar clinical severity at presentation 
(systolic blood pressure 122.2+24.2 versus 127.8+24.1 mmHg, hypotension in 5.9% ver- 
sus 3.4%, and right ventricular hypokinesis in 52.5% versus 30.8% patients, respectively, 
all differences non-significant). 
Concluaions: RHTh confer an ominous prognosis with increased early mortality, espe- 
cially evident in patients treated with heparin alone. These findings suggest that patients 
with acute PE who have RHTh should be managed with more aggressive therapy than 
heparin anticoagulation alone, even when hemodynamically stable at the time of presen- 
tation. 
4:30 p.m. 
873-3 Compar i son  o f  Narrow Versus Standard Target INR 
Ranges 
David J. Mej@r, Seema S. Sonnad, Julie C. Merz, William P. Fay, University of Michigan, 
Ann Arbor, Michigan. 
Background: Although current guidelines suggest a target INR range of 2.0-3.0 or 2.5- 
3.5 for most patients, physicians frequently select narrow target INR ranges (e.g. 2.0-2.5) 
in an attempt to minimize complications. However, the efficacies of narrow versus stan- 
dard target INR ranges are unknown. We hypothesized that narrow range management 
results in a greater frequency of INRs <2.0 or >4.0. which are associated with an 
increased dsk of thrombotic and bleeding complications, respectively. 
Methods: We identified 32 patients managed with both a narrow and a standard range 
strategy during their course of anticoagulation. Over 3000 INRs during 133 patient-years 
of follow-up were obtained. Sixteen patients were managed with both a 2.0-3.0 and a 
2.0-2.5 range (Group A) and 16 patients were managed with both a 2.5-3.5 and a 3.0-3.5 
range (Group B). 
Results: Blood draws per month were more frequent (2.0_+0.2 vs. 1.7_+0.1 ; p=0.035) dur- 
ing narrow range management for both groups combined. For Group A, mean INR was 
lower (2.4_+0.03 vs. 2.6_+0.06; p<0.02) and frequency of INRs <2.0 was higher (23.6_+2.4 
vs. 17.2_+2.7; p<0.04) during narrow range management. For Group S, mean INR was 
higher (3.4±0.03 vs. 3,1±0.06; p<0.001) and frequency of INRs >4.0 was higher 
(21.2_+1.4 vs. 13.0±2.3; p<0.007) during narrow range management. 
Conclusions: Compared to a target INR range of 2.0-3.0, management with a target 
range of 2.0-2.5 increases the frequency of INRs <2.0, which are associated with an 
increased risk of thrombotic complications. Conversely, compared to a target range of 
2.5-3.5, management with a target range of 3.0-3.5 increases the frequency of INRs 
>4.0, which are associated with a significantly increased risk of hemorrhagic complica- 
tions. Narrow target INR ranges also increase the cost and patient inconvenience associ- 
ated with anticoagulant herapy. Physicians should take these issues into account before 
selecting narrow target INR ranges for their patients. 
4:45 p.m. 
873-4 Alteplase Improves the Clinical Course of  Pat ients  With 
Major Pulmonary Embolism: A Multicenter, 
Randomized, Placebo-Controlled Trial (Management 
Strategies  and Prognosis in Pulmonary Embolism 
Study 3) 
Stavros Konstantinides. Annette Geibel, Wolfgang Kasper, University of Goettingen, 
Department of Cardiology and Pulmonary Medicine, Goettingen, Germany, St. Josefs 
Hospital, Wiesbaden, Germany. 
Background: The clinical benefit of thrombolytic treatment in patients with major pulmo- 
nary embolism (PE) who appear stable at presentation remains highly controversial. 
Methods: In a prospective, multicenter, placebo-controlled trial, 250 consecutive patients 
with PE confirmed by lung scan, spiral CT, or pulmonary angiography were enrolled and 
247 of them randomly assigned to treatment with aiteplase (100 mg infusion over 2 h) 
plus heparin or heparin alone. Patients bad major PE defined as 1) echocardiographic 
findings of right ventdcular enlargement and/or pulmonary hypertension; 2) new-onset 
right heart strain on the ECG; or, 3) precapillary pulmonary hypertension on Swanz-Ganz 
catheterization. Patients with peristent arterial hypotension, cardiogenic shock, or need 
for cardiopulmonary resuscitation (CPR) at presentation were excluded. The primary end 
point was 30-day mortality or escalation/change of therapy (defined as need for breaking 
the code and/or one of the following: catecholamine infusion, endotracheal intubation, 
CPR, or emergency thrombolysis, catheter fragmentation, or surgical embolectomy) at 
least 2 h after randomization. 
Results: Alteplase was given to 115 (47%) and heparin alone to 132 (53%) pts. No dif- 
ferencas existed between the 2 groups with regard to the clinical symptoms, physical 
examination, radiologic, ECG, echocardiographic, or laboratory findings at randomiza- 
tion. The primary end point was reached in 31 pts (24%) of the heparin group compared 
with only 14 (12%) of those in the thrombolysis group (p=0.021). This difference was 
largely due to the more frequent need for escalation of therapy in the heparin vs. throm- 
bolysis group (24 vs. 11%; p=0.01), since mortality was iow in both groups (2 and 4 pts 
respectively; p=0.42). Major bleeding was 3% in the heparin and 0.9% in the aiteplase 
group (p=0.38), whereas hemorrhagic stroke occurred in only 1 patient (0.8%) in each 
group. 
Conclusion: In this largest to-date randomized trial of thrombolysis vs. heparin for PE, 
altaplase was found to favorably affect the clinical course of pts with major PE appearing 
hemodynamically stable at presentation, although it did not reduce in-hospital mortality. 
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881-1 The Association Between In f lammatory  Markers and 
Thrombogenic Factors  in Pos t in fa rcUon Pat ients  
Tares S. Harb. Wojciech Zareba. Arthur J. Moss. Paul M. Ridker, Neder Ritai, Victor J. 
Marder, Luc Miller-Watelet, University of Rochester Medic.a/Center, Rochester, New 
York. 
Background: Dyslipidemia, inflammation and thrombosis are all implicated in the patho- 
physiology of plaque instability and rupture. To better understand the association among 
these mechanisms, we investigated the relationship between levels of inflammatory 
markers C-reactive protein (CRP) and serum amyloid A (SAA) and thrombogenic and 
lipid factors in patients with established coronary artery disease. 
Methods: Blood levels of CRP, SAA and various thrembogenic and lipid factors were 
measured 2 months after an index myocardial infarction in 957 patients. Multivariate 
analyses were used to determine the relationship between levels of inflammatory mark- 
ers and levels of lipid and thrombogenic factors. 
Results: In multivariate analysis, elevated CRP and SAA (->75 th pementile) were associ- 
ated with increased levels (p<0.00t) of several thrombogenic factors as summarized in 
the table below. Conversely, neither inflammatory marker was significantly associated 
with levels of lipid factors. 
Conclusion: In stable post-infarction patients, there is a significant association between 
levels of inflammatory markers and thrembogenic factors. Conversely, levels of inflam- 
matory markers are not significantly associated with the degree of dyslipidemia. This 
data suggests a possible mechanistic relationship between inflammation and thrombosis 
in patients with established coronary artery disease. 
Elevated CRP Elevated SAA 
OR CI* OR CI* 
vWF 2.21 1.50-3.25 2.79 1.88-4.14 
FIbrinogen 1,013 1,011-1,016 1.010 1.008-1.012 
D-Dlmer 1.85 t .46-2.35 2.10 1.65-2.68 
* - p<0.001 
vWF - von Willebrand Factor 
CI - 95% Confidence Interval 
OR - Odds Ratio (expressed per 1 log unit increase in vWF and D-Dimer and per 1 rag/ 
dl % increase in fibdnogen) 
8:45 a.m. 
881-2 C-Reactive Protein Predicts Microalbuminuria 
p.drian W. Messerli, Ravish Sachar, Gregory L. Pearce, Byron J. Hoogwerf, Dennis L 
Sprecher, The Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: Inflammation leads to endothelial dysfunction. It has been proposed that 
endothelial changes can lead to small losses of protein from the renal glomeruli. If C- 
reactive protein (CRP) is a marker for inflammation, then it may predict microalbuminuria. 
Methods: We analysed serum CRP and urine albumin/creatinine ratios (ACR) from 343 
patients (n=52, diabetics) drawn from our preventive cardiology clinic. ACR values >20 
mg/g were used as the cutpoint, approximating the upper quartile presented in the HOPE 
trial. Quinfiles of CRP from our population were utilized. Results: Logistic regression 
models were constructed to determine the relative risk of microalbuminuria ssociated 
with each quintile increase in CRP. Three models were run: (1) unadjusted, (2) Framing- 
ham adjusted, and (3) Framingham + CAD status adjusted. All three models show that 
CRP partially explains the level of microalbuminuria for each successive CRP quintile 
(see table). In contrast to a previous cohort analysis, further adjustment for fibrinogen, 
waist, and glucose level did not change the outcome. Conclusions: Each progressively 
higher CRP quartile predicts an additional 30% risk for the presence of microalbuminuria. 
These data are consistent with and further substantiate the relationship between inflam- 
mation and renovascular endothelial dysfunction. 
Logistic regression of RR for ACR >20 mg/g 
DM ALL 
OR (95% C.I) p-value OR (95% C.I.) p-value 
Unadjusted 2.08 (1.15-3.68) 0.01 1.38 (1.12-1.72) 0.003 
Framingham Adjustment 2.06 (1.16-3.66) 0.01 1.31 (1.05 - 1.63) 0.02 
Framingham + CAD 2.05 (1.15-3.67) 0.02 1.32 (1.05-1.66) 0.02 
